ACM
ACRS icon

ADAR1 Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

ADAR1 Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$497K Sell
132,426
-481,560
-78% -$1.62M 0.03% 202
2025
Q4 		$1.85M Buy
613,986
+240,304
+64% +$607K 0.14% 104
2025
Q3 		$710K Buy
+373,682
New +$651K 0.07% 115
2024
Q4 		– Sell
-90,000
Closed -$104K – 217
2024
Q3 		$104K Buy
+90,000
New +$110K 0.02% 186

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ADAR1 Capital Management's ACRS Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 78% in Q1 2026, selling an estimated $1.62M and leaving 132,426 shares worth $497K. The position accounts for 0.03% of the portfolio, ranked #202.

ADAR1 Capital Management first reported a position in ACRS in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.85M in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • ADAR1 Capital Management held 132,426 shares of Aclaris Therapeutics worth $497K as of Q1 2026.
  • ADAR1 Capital Management sold 481,560 Aclaris Therapeutics shares in Q1 2026, an estimated $1.62M.
  • Aclaris Therapeutics made up 0.03% of ADAR1 Capital Management's portfolio in Q1 2026, its #202 holding.
  • ADAR1 Capital Management first reported a position in Aclaris Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • ADAR1 Capital Management's Aclaris Therapeutics position peaked at $1.85M in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.